{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:51:23Z","timestamp":1793501483112,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00134-025-07873-6","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T21:32:22Z","timestamp":1743543142000},"page":"756-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Sepsis subphenotypes, theragnostics and personalized sepsis care"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-9160","authenticated-orcid":false,"given":"David B.","family":"Antcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"McAuley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Silversides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"7873_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"7873_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM et al (2020) Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet 395:200\u2013211. https:\/\/doi.org\/10.1016\/S0140-6736(19)32989-7","journal-title":"Lancet"},{"key":"7873_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC (2014) Why have clinical trials in sepsis failed? Trends Mol Med 20:195\u2013203. https:\/\/doi.org\/10.1016\/j.molmed.2014.01.007","journal-title":"Trends Mol Med"},{"key":"7873_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2213-2600(23)00468-X","volume":"12","author":"M Shankar-Hari","year":"2024","unstructured":"Shankar-Hari M, Calandra T, Soares MP et al (2024) Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respir Med 12:323. https:\/\/doi.org\/10.1016\/S2213-2600(23)00468-X","journal-title":"Lancet Respir Med"},{"key":"7873_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00134-018-5175-z","volume":"44","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, De Backer D, Deutschman CS et al (2018) Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med 44:1400\u20131426. https:\/\/doi.org\/10.1007\/s00134-018-5175-z","journal-title":"Intensive Care Med"},{"key":"7873_CR6","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/S2213-2600(24)00298-4","volume":"12","author":"J McPeake","year":"2024","unstructured":"McPeake J, Oakes M, Graham C et al (2024) Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership. Lancet Respir Med 12:e68\u2013e69. https:\/\/doi.org\/10.1016\/S2213-2600(24)00298-4","journal-title":"Lancet Respir Med"},{"key":"7873_CR7","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMOA1202290\/SUPPL_FILE\/NEJMOA1202290_DISCLOSURES.PDF","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Thompson BT, Barie PS et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055\u20132064. https:\/\/doi.org\/10.1056\/NEJMOA1202290\/SUPPL_FILE\/NEJMOA1202290_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S et al (2019) Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 321:2003\u20132017. https:\/\/doi.org\/10.1001\/jama.2019.5791","journal-title":"JAMA"},{"key":"7873_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jcrc.2018.06.012","volume":"47","author":"B G\u00e5rdlund","year":"2018","unstructured":"G\u00e5rdlund B, Dmitrieva NO, Pieper CF et al (2018) Six subphenotypes in septic shock: latent class analysis of the PROWESS Shock study. J Crit Care 47:70\u201379. https:\/\/doi.org\/10.1016\/j.jcrc.2018.06.012","journal-title":"J Crit Care"},{"key":"7873_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/THORAX-2023-220538","volume":"79","author":"DB Antcliffe","year":"2024","unstructured":"Antcliffe DB, Mi Y, Santhakumaran S et al (2024) Patient stratification using plasma cytokines and their regulators in sepsis: relationship to outcomes, treatment effect and leucocyte transcriptomic subphenotypes. Thorax 79:515\u2013523. https:\/\/doi.org\/10.1136\/THORAX-2023-220538","journal-title":"Thorax"},{"key":"7873_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","volume":"5","author":"BP Scicluna","year":"2017","unstructured":"Scicluna BP, van Vught LA, Zwinderman AH et al (2017) Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 5:816\u2013826. https:\/\/doi.org\/10.1016\/S2213-2600(17)30294-1","journal-title":"Lancet Respir Med"},{"key":"7873_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","volume":"4","author":"EE Davenport","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J et al (2016) Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4:259\u2013271","journal-title":"Lancet Respir Med"},{"key":"7873_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S2213-2600(23)00237-0","volume":"11","author":"P Sinha","year":"2023","unstructured":"Sinha P, Kerchberger E, Willmore A et al (2023) Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med 11:965\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(23)00237-0","journal-title":"Lancet Respir Med"},{"key":"7873_CR14","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1186\/CC11667","volume":"16","author":"DM Maslove","year":"2012","unstructured":"Maslove DM, Tang BM, McLean AS (2012) Identification of sepsis subtypes in critically ill adults using gene expression profiling. Crit Care 16:R183. https:\/\/doi.org\/10.1186\/CC11667","journal-title":"Crit Care"},{"key":"7873_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","volume":"28","author":"DM Maslove","year":"2022","unstructured":"Maslove DM, Tang B, Shankar-Hari M et al (2022) Redefining critical illness. Nat Med 28:1141\u20131148. https:\/\/doi.org\/10.1038\/s41591-022-01843-x","journal-title":"Nat Med"},{"key":"7873_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41571-019-0273-6","volume":"17","author":"JT Yurkovich","year":"2019","unstructured":"Yurkovich JT, Tian Q, Price ND, Hood L (2019) A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol 17:183\u2013194. https:\/\/doi.org\/10.1038\/s41571-019-0273-6","journal-title":"Nat Rev Clin Oncol"},{"key":"7873_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/S12016-018-8712-1","volume":"56","author":"ME Kuruvilla","year":"2019","unstructured":"Kuruvilla ME, Lee FEH, Lee GB (2019) Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 56:219. https:\/\/doi.org\/10.1007\/S12016-018-8712-1","journal-title":"Clin Rev Allergy Immunol"},{"key":"7873_CR18","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/S00134-024-07593-3","volume":"50","author":"N Bruse","year":"2024","unstructured":"Bruse N, Motos A, van Amstel R et al (2024) Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients. Intensive Care Med 50:1884\u20131896. https:\/\/doi.org\/10.1007\/S00134-024-07593-3","journal-title":"Intensive Care Med"},{"key":"7873_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/S13054-021-03734-Y","volume":"25","author":"X Liu","year":"2021","unstructured":"Liu X, Jiang Y, Jia X et al (2021) Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment. Crit Care 25:320. https:\/\/doi.org\/10.1186\/S13054-021-03734-Y","journal-title":"Crit Care"},{"key":"7873_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1164\/rccm.201608-1685OC","volume":"196","author":"KL Burnham","year":"2017","unstructured":"Burnham KL, Davenport EE, Radhakrishnan J et al (2017) Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med 196:328\u2013339. https:\/\/doi.org\/10.1164\/rccm.201608-1685OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1126\/SCITRANSLMED.ADH0185\/SUPPL_FILE\/SCITRANSLMED.ADH0185_MDAR_REPRODUCIBILITY_CHECKLIST.PDF","volume":"16","author":"Y Mi","year":"2024","unstructured":"Mi Y, Burnham KL, Charles PD et al (2024) High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response. Sci Transl Med 16:185. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ADH0185\/SUPPL_FILE\/SCITRANSLMED.ADH0185_MDAR_REPRODUCIBILITY_CHECKLIST.PDF","journal-title":"Sci Transl Med"},{"key":"7873_CR22","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-023-07239-w","volume":"49","author":"RBE Van Amstel","year":"2023","unstructured":"Van Amstel RBE, Kennedy JN, Scicluna BP et al (2023) Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes on behalf of the MARS consortium. Intensive Care Med 49:1360\u20131369. https:\/\/doi.org\/10.1007\/s00134-023-07239-w","journal-title":"Intensive Care Med"},{"issue":"5","key":"7873_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41590-023-01490-5","volume":"24","author":"AJ Kwok","year":"2023","unstructured":"Kwok AJ, Allcock A, Ferreira RC et al (2023) Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis. Nat Immunol 24(5):767\u2013779. https:\/\/doi.org\/10.1038\/s41590-023-01490-5","journal-title":"Nat Immunol"},{"key":"7873_CR24","doi-asserted-by":"publisher","first-page":"eabq4433","DOI":"10.1126\/SCITRANSLMED.ABQ4433","volume":"14","author":"E Cano-Gamez","year":"2022","unstructured":"Cano-Gamez E, Burnham KL, Goh C et al (2022) An immune dysfunction score for stratification of patients with acute infection based on whole blood gene expression. Sci Transl Med 14:eabq4433. https:\/\/doi.org\/10.1126\/SCITRANSLMED.ABQ4433","journal-title":"Sci Transl Med"},{"key":"7873_CR25","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1038\/S41467-024-48821-0","volume":"15","author":"JG Chenoweth","year":"2024","unstructured":"Chenoweth JG, Colantuoni C, Striegel DA et al (2024) Gene expression signatures in blood from a West African sepsis cohort define host response phenotypes. Nat Commun 15:4606. https:\/\/doi.org\/10.1038\/S41467-024-48821-0","journal-title":"Nat Commun"},{"key":"7873_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/CCM.0000000000003084","volume":"46","author":"TE Sweeney","year":"2018","unstructured":"Sweeney TE, Azad TD, Donato M et al (2018) Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med 46:915\u2013925. https:\/\/doi.org\/10.1097\/CCM.0000000000003084","journal-title":"Crit Care Med"},{"key":"7873_CR27","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1097\/CCM.0000000000004786","volume":"49","author":"TE Sweeney","year":"2021","unstructured":"Sweeney TE, Liesenfeld O, Wacker J et al (2021) Validation of inflammopathic, adaptive, and coagulopathic sepsis endotypes in coronavirus disease 2019. Crit Care Med 49:E170\u2013E178. https:\/\/doi.org\/10.1097\/CCM.0000000000004786","journal-title":"Crit Care Med"},{"key":"7873_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-7-34","volume":"7","author":"HR Wong","year":"2009","unstructured":"Wong HR, Cvijanovich N, Lin R et al (2009) Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 7:1\u201312. https:\/\/doi.org\/10.1186\/1741-7015-7-34","journal-title":"BMC Med"},{"key":"7873_CR29","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1097\/CCM.0000000000002733","volume":"45","author":"HR Wong","year":"2017","unstructured":"Wong HR, Sweeney TE, Hart KW et al (2017) Pediatric sepsis endotypes among adults with sepsis. Crit Care Med 45:e1289\u2013e1291. https:\/\/doi.org\/10.1097\/CCM.0000000000002733","journal-title":"Crit Care Med"},{"key":"7873_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079207","volume":"8","author":"CD Fjell","year":"2013","unstructured":"Fjell CD, Thair S, Hsu JL et al (2013) Cytokines and signaling molecules predict clinical outcomes in sepsis. PLoS ONE 8:e79207. https:\/\/doi.org\/10.1371\/journal.pone.0079207","journal-title":"PLoS ONE"},{"key":"7873_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fimmu.2018.00691","volume":"9","author":"KA Mosevoll","year":"2018","unstructured":"Mosevoll KA, Skrede S, Markussen DL et al (2018) Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Front Immunol 9:691. https:\/\/doi.org\/10.3389\/fimmu.2018.00691","journal-title":"Front Immunol"},{"key":"7873_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE et al (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2:611\u2013620. https:\/\/doi.org\/10.1016\/S2213-2600(14)70097-9","journal-title":"Lancet Respir Med"},{"key":"7873_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/S00134-018-5378-3","volume":"44","author":"P Sinha","year":"2018","unstructured":"Sinha P, Delucchi KL, Thompson BT et al (2018) Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med 44:1859. https:\/\/doi.org\/10.1007\/S00134-018-5378-3","journal-title":"Intensive Care Med"},{"key":"7873_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous KR, Delucchi K, Ware LB et al (2017) acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195:331\u2013338. https:\/\/doi.org\/10.1164\/rccm.201603-0645OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/THORAXJNL-2021-217158","volume":"77","author":"P Sinha","year":"2022","unstructured":"Sinha P, Delucchi KL, Chen Y et al (2022) Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study. Thorax 77:13\u201321. https:\/\/doi.org\/10.1136\/THORAXJNL-2021-217158","journal-title":"Thorax"},{"key":"7873_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1164\/RCCM.202105-1302OC\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"204","author":"P Sinha","year":"2021","unstructured":"Sinha P, Furfaro D, Cummings MJ et al (2021) Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med 204:1274\u20131285. https:\/\/doi.org\/10.1164\/RCCM.202105-1302OC\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR37","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee CS, Delucchi KL, Sinha P et al (2018) ARDS subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. Lancet Respir Med 6:691. https:\/\/doi.org\/10.1016\/S2213-2600(18)30177-2","journal-title":"Lancet Respir Med"},{"key":"7873_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(19)30369-8","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha P, Delucchi KL, McAuley DF et al (2020) Development and validation of parsimonious algorithms to classify ARDS phenotypes: secondary analyses of randomised controlled trials. Lancet Respir Med 8:247. https:\/\/doi.org\/10.1016\/S2213-2600(19)30369-8","journal-title":"Lancet Respir Med"},{"key":"7873_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1164\/RCCM.202002-0347OC\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"202","author":"P Sinha","year":"2020","unstructured":"Sinha P, Churpek MM, Calfee CS (2020) Machine learning classifier models can identify acute respiratory distress syndrome phenotypes using readily available clinical data. Am J Respir Crit Care Med 202:996\u20131004. https:\/\/doi.org\/10.1164\/RCCM.202002-0347OC\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F et al (2020) Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 324:1317\u20131329. https:\/\/doi.org\/10.1001\/jama.2020.17022","journal-title":"JAMA"},{"key":"7873_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1705716","volume":"378","author":"D Annane","year":"2018","unstructured":"Annane D, Renault A, Brun-Buisson C et al (2018) Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378:809\u2013818. https:\/\/doi.org\/10.1056\/NEJMoa1705716","journal-title":"N Engl J Med"},{"key":"7873_CR42","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMOA2215145\/SUPPL_FILE\/NEJMOA2215145_DATA-SHARING.PDF","volume":"388","author":"P-F Dequin","year":"2023","unstructured":"Dequin P-F, Meziani F, Quenot J-P et al (2023) Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 388:1931\u20131941. https:\/\/doi.org\/10.1056\/NEJMOA2215145\/SUPPL_FILE\/NEJMOA2215145_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1705835","volume":"378","author":"B Venkatesh","year":"2018","unstructured":"Venkatesh B, Finfer S, Cohen J et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797\u2013808. https:\/\/doi.org\/10.1056\/NEJMoa1705835","journal-title":"N Engl J Med"},{"key":"7873_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N et al (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509\u2013518. https:\/\/doi.org\/10.1001\/jama.2016.10485","journal-title":"JAMA"},{"key":"7873_CR45","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F et al (2019) Transcriptomic signatures in sepsis and a differential response to steroids from the VANISH randomized trial. Am J Respir Crit Care Med 199:980\u2013986. https:\/\/doi.org\/10.1164\/rccm.201807-1419OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1164\/rccm.201410-1864OC","volume":"191","author":"HR Wong","year":"2015","unstructured":"Wong HR, Cvijanovich NZ, Anas N et al (2015) Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med 191:309\u2013315. https:\/\/doi.org\/10.1164\/rccm.201410-1864OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR47","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/CCM.0000000000004709","volume":"49","author":"HR Wong","year":"2021","unstructured":"Wong HR, Hart KW, Lindsell CJ, Sweeney TE (2021) External corroboration that corticosteroids may be harmful to septic shock endotype A patients. Crit Care Med 49:e98\u2013e101. https:\/\/doi.org\/10.1097\/CCM.0000000000004709","journal-title":"Crit Care Med"},{"key":"7873_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2197-425X-2-9","volume":"2","author":"J Morel","year":"2014","unstructured":"Morel J, Singer M (2014) Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target? Intensive Care Med Exp 2:9. https:\/\/doi.org\/10.1186\/2197-425X-2-9","journal-title":"Intensive Care Med Exp"},{"key":"7873_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/IMM.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser R (2018) Immune modulatory effects of statins. Immunology 154:69. https:\/\/doi.org\/10.1111\/IMM.12902","journal-title":"Immunology"},{"key":"7873_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/J.CHEST.2017.09.024","volume":"153","author":"CC Lee","year":"2018","unstructured":"Lee CC, Lee MG, Hsu TC et al (2018) A population-based cohort study on the drug-specific effect of statins on sepsis outcome. Chest 153:805\u2013815. https:\/\/doi.org\/10.1016\/J.CHEST.2017.09.024","journal-title":"Chest"},{"key":"7873_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1164\/RCCM.201209-1718OC","volume":"187","author":"P Kruger","year":"2013","unstructured":"Kruger P, Bailey M, Bellomo R et al (2013) A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 187:743\u2013750. https:\/\/doi.org\/10.1164\/RCCM.201209-1718OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR52","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1056\/NEJMOA2309995","volume":"389","author":"The REMAP-CAP Investigators","year":"2023","unstructured":"The REMAP-CAP Investigators (2023) Simvastatin in critically ill patients with Covid-19. N Engl J Med 389:2341\u20132354. https:\/\/doi.org\/10.1056\/NEJMOA2309995","journal-title":"N Engl J Med"},{"key":"7873_CR53","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMOA1403285\/SUPPL_FILE\/NEJMOA1403285_DISCLOSURES.PDF","volume":"371","author":"DF McAuley","year":"2014","unstructured":"McAuley DF, Laffey JG, O\u2019Kane CM et al (2014) Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371:1695\u20131703. https:\/\/doi.org\/10.1056\/NEJMOA1403285\/SUPPL_FILE\/NEJMOA1403285_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR54","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMOA1401520\/SUPPL_FILE\/NEJMOA1401520_DISCLOSURES.PDF","volume":"370","author":"TNH Lung","year":"2014","unstructured":"Lung TNH, Blood Institute ARDS, Network CT (2014) Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370:2191\u20132200. https:\/\/doi.org\/10.1056\/NEJMOA1401520\/SUPPL_FILE\/NEJMOA1401520_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR55","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/S13054-022-04025-W","volume":"26","author":"AJ Boyle","year":"2022","unstructured":"Boyle AJ, Ferris P, Bradbury I et al (2022) Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. Crit Care 26:164. https:\/\/doi.org\/10.1186\/S13054-022-04025-W","journal-title":"Crit Care"},{"key":"7873_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006028","volume":"51","author":"AR Moore","year":"2023","unstructured":"Moore AR, Pienkos SM, Sinha P et al (2023) Elevated plasma IL-18 identifies high-risk ARDS patients not distinguished by prior latent class analyses using traditional inflammatory cytokines: a retrospective analysis of the SAILS and HARP-2 randomized clinical trials. Crit Care Med 51:e269. https:\/\/doi.org\/10.1097\/CCM.0000000000006028","journal-title":"Crit Care Med"},{"key":"7873_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/CC4946\/FIGURES\/2","volume":"10","author":"AF Shorr","year":"2006","unstructured":"Shorr AF, Bernard GR, Dhainaut JF et al (2006) Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. Crit Care 10:1\u20138. https:\/\/doi.org\/10.1186\/CC4946\/FIGURES\/2","journal-title":"Crit Care"},{"key":"7873_CR58","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1378\/CHEST.120.3.915","volume":"120","author":"SB Yan","year":"2001","unstructured":"Yan SB, Helterbrand JD, Hartman DL et al (2001) Low levels of protein c are associated with poor outcome in severe sepsis. Chest 120:915\u2013922. https:\/\/doi.org\/10.1378\/CHEST.120.3.915","journal-title":"Chest"},{"key":"7873_CR59","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1097\/01.CCM.0000126120.49367.AC","volume":"32","author":"WL Macias","year":"2004","unstructured":"Macias WL, Nelson DR (2004) Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32:S223\u2013S228. https:\/\/doi.org\/10.1097\/01.CCM.0000126120.49367.AC","journal-title":"Crit Care Med"},{"key":"7873_CR60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJM200103083441001\/ASSET\/9726D43B-B3FC-47BD-BAF4-15AAC53C2BF2\/ASSETS\/IMAGES\/LARGE\/NEJM200103083441001_T7.JPG","volume":"344","author":"GR Bernard","year":"2001","unstructured":"Bernard GR, Vincent J-L, Laterre P-F et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699\u2013709. https:\/\/doi.org\/10.1056\/NEJM200103083441001\/ASSET\/9726D43B-B3FC-47BD-BAF4-15AAC53C2BF2\/ASSETS\/IMAGES\/LARGE\/NEJM200103083441001_T7.JPG","journal-title":"N Engl J Med"},{"key":"7873_CR61","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/JAMA.2021.18178","volume":"326","author":"Writing Committee for the REMAP-CAP Investigators","year":"2021","unstructured":"Writing Committee for the REMAP-CAP Investigators (2021) Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: a randomized clinical trial. JAMA 326:1690\u20131702. https:\/\/doi.org\/10.1001\/JAMA.2021.18178","journal-title":"JAMA"},{"key":"7873_CR62","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00134-022-06869-w","volume":"48","author":"M Fish","year":"2022","unstructured":"Fish M, Rynne J, Jennings A et al (2022) Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial on behalf of the REMAP-CAP Immunoglobulin Domain UK Investigators. Intensive Care Med 48:1525\u20131538. https:\/\/doi.org\/10.1007\/s00134-022-06869-w","journal-title":"Intensive Care Med"},{"key":"7873_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-023-01766-7","volume":"9","author":"M Cao","year":"2023","unstructured":"Cao M, Wang G, Xie J (2023) Immune dysregulation in sepsis: experiences, lessons and perspectives. Cell Death Discov 9:1\u201311. https:\/\/doi.org\/10.1038\/s41420-023-01766-7","journal-title":"Cell Death Discov"},{"key":"7873_CR64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMOA032193\/SUPPL_FILE\/327SA1.PDF","volume":"351","author":"TNH Lung","year":"2004","unstructured":"Lung TNH, Blood Institute ARDS, Network CT (2004) Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 351:327\u2013336. https:\/\/doi.org\/10.1056\/NEJMOA032193\/SUPPL_FILE\/327SA1.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR65","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.chest.2024.04.011","volume":"166","author":"MT Siuba","year":"2024","unstructured":"Siuba MT, Bulgarelli L, Duggal A et al (2024) Differential effect of PEEP strategies in ARDS patients: a Bayesian analysis of clinical subphenotypes. Chest 166:754\u2013764. https:\/\/doi.org\/10.1016\/j.chest.2024.04.011","journal-title":"Chest"},{"key":"7873_CR66","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1056\/NEJMOA062200\/SUPPL_FILE\/NEJMOA062200SA1.PDF","volume":"354","author":"HP Wiedemann","year":"2006","unstructured":"Wiedemann HP, Clinic C, Wheeler AP et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564\u20132575. https:\/\/doi.org\/10.1056\/NEJMOA062200\/SUPPL_FILE\/NEJMOA062200SA1.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR67","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa067373","volume":"358","author":"JA Russell","year":"2008","unstructured":"Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa067373","journal-title":"N Engl J Med"},{"key":"7873_CR68","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1164\/RCCM.201807-1346OC","volume":"199","author":"PK Bhatraju","year":"2019","unstructured":"Bhatraju PK, Zelnick LR, Herting J et al (2019) Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. Am J Respir Crit Care Med 199:863\u2013872. https:\/\/doi.org\/10.1164\/RCCM.201807-1346OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"O Abani","year":"2022","unstructured":"Abani O, Abbas A, Abbas F et al (2022) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 400:359\u2013368. https:\/\/doi.org\/10.1016\/S0140-6736(22)01109-6","journal-title":"Lancet"},{"key":"7873_CR70","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F et al (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637\u20131645. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"7873_CR71","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMOA2100433\/SUPPL_FILE\/NEJMOA2100433_DATA-SHARING.PDF","volume":"384","author":"REMAP-CAP Investigators","year":"2021","unstructured":"Investigators REMAP-CAP (2021) Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 384:1491\u20131502. https:\/\/doi.org\/10.1056\/NEJMOA2100433\/SUPPL_FILE\/NEJMOA2100433_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13054-023-04492-9\/TABLES\/3","volume":"27","author":"S Becker","year":"2023","unstructured":"Becker S, Lang H, Vollmer Barbosa C et al (2023) Efficacy of CytoSorb\u00ae: a systematic review and meta-analysis. Crit Care 27:1\u201313. https:\/\/doi.org\/10.1186\/S13054-023-04492-9\/TABLES\/3","journal-title":"Crit Care"},{"key":"7873_CR73","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.4049\/JIMMUNOL.1202062","volume":"189","author":"F Venet","year":"2012","unstructured":"Venet F, Foray A-P, Villars-M\u00e9chin A et al (2012) IL-7 restores lymphocyte functions in septic patients. J Immunol 189:5073\u20135081. https:\/\/doi.org\/10.4049\/JIMMUNOL.1202062","journal-title":"J Immunol"},{"key":"7873_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0199497","volume":"13","author":"LK Thampy","year":"2018","unstructured":"Thampy LK, Remy KE, Walton AH et al (2018) Restoration of T cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration. PLoS ONE 13:e0199497. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0199497","journal-title":"PLoS ONE"},{"key":"7873_CR75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.98960","volume":"3","author":"B Francois","year":"2018","unstructured":"Francois B, Jeannet R, Daix T et al (2018) Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3:e98960. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.98960","journal-title":"JCI Insight"},{"key":"7873_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/S13613-023-01109-W","volume":"13","author":"T Daix","year":"2023","unstructured":"Daix T, Mathonnet A, Brakenridge S et al (2023) Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care 13:17. https:\/\/doi.org\/10.1186\/S13613-023-01109-W","journal-title":"Ann Intensive Care"},{"key":"7873_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-62202-z","volume":"14","author":"E Peronnet","year":"2024","unstructured":"Peronnet E, Terraz G, Cerrato E et al (2024) Use of immune profiling panel to assess the immune response of septic patients for prediction of worsening as a composite endpoint. Sci Rep 14:1\u201310. https:\/\/doi.org\/10.1038\/s41598-024-62202-z","journal-title":"Sci Rep"},{"key":"7873_CR78","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CCM.0000000000005832","volume":"51","author":"E Peronnet","year":"2023","unstructured":"Peronnet E, Blein S, Venet F et al (2023) Immune profiling panel gene set identifies critically ill patients with low monocyte human leukocyte antigen-DR expression: preliminary results from the reanimation low immune status marker (REALISM) study. Crit Care Med 51:808. https:\/\/doi.org\/10.1097\/CCM.0000000000005832","journal-title":"Crit Care Med"},{"key":"7873_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13054-025-05319-5","volume":"29","author":"DB Antcliffe","year":"2025","unstructured":"Antcliffe DB, Peronnet E, P\u00e8ne F et al (2025) An international observational study validating gene-expression sepsis immune subgroups. Crit Care 29:1\u201311. https:\/\/doi.org\/10.1186\/S13054-025-05319-5","journal-title":"Crit Care"},{"key":"7873_CR80","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1164\/RCCM.202401-0101CP\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"209","author":"PRACTICAL; PANTHER; TRAITS; INCEPT; and REMAP-CAP investigators","year":"2024","unstructured":"PRACTICAL; PANTHER; TRAITS; INCEPT; and REMAP-CAP investigators (2024) The rise of adaptive platform trials in critical Care. Am J Respir Crit Care Med 209:491\u2013496. https:\/\/doi.org\/10.1164\/RCCM.202401-0101CP\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2022-067251","volume":"12","author":"A Kotsaki","year":"2022","unstructured":"Kotsaki A, Pickkers P, Bauer M et al (2022) ImmunoSep (personalised immunotherapy in sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open 12:e067251. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-067251","journal-title":"BMJ Open"},{"key":"7873_CR82","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/S00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli G, Calfee CS, Camporota L et al (2023) ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 49:727. https:\/\/doi.org\/10.1007\/S00134-023-07050-7","journal-title":"Intensive Care Med"},{"key":"7873_CR83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/RCCM.202311-2086SO\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"2","author":"AC Gordon","year":"2024","unstructured":"Gordon AC, Alipanah-Lechner N, Bos LD et al (2024) From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in ICU. Am J Respir Crit Care Med 2:155\u2013166. https:\/\/doi.org\/10.1164\/RCCM.202311-2086SO\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Crit Care Med"},{"key":"7873_CR84","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1056\/NEJMOA1401602\/SUPPL_FILE\/NEJMOA1401602_DISCLOSURES.PDF","volume":"370","author":"The ProCESS Investigators","year":"2014","unstructured":"The ProCESS Investigators (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683\u20131693. https:\/\/doi.org\/10.1056\/NEJMOA1401602\/SUPPL_FILE\/NEJMOA1401602_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"7873_CR85","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/JAMA.2017.14171","volume":"318","author":"AB Cavalcanti","year":"2017","unstructured":"Cavalcanti AB, Suzumura \u00c9A, Laranjeira LN et al (2017) Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA 318:1335\u20131345. https:\/\/doi.org\/10.1001\/JAMA.2017.14171","journal-title":"JAMA"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-025-07873-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07873-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:44:41Z","timestamp":1746510281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-025-07873-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7873"],"URL":"https:\/\/doi.org\/10.1007\/s00134-025-07873-6","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ACG reports that outside of this work he has received grant funding from the National Institute for Health and Care Research. AB reports grant funding from the NHMRC. AJB reports grant funding from the Belfast Health and Social Care Trust Charity and support from ViroGates. ACG reports that outside of this work he has received consulting fees from AstraZeneca, Beckman Coulter, and VVB Bio, speaker fees from Fresenius Kabi and grant support from the NIHR HTA programme. ACG is the director of the NIHR National Research Collaboration Programme. Outside the submitted work, DFM reports personal fees for consultancy from Bayer, GSK, Boehringer Ingelheim, Eli Lilly, Novartis and SOBI and for being a member of the data monitoring and ethics committee for Vir Biotechnology and Faron studies and as an educational seminar speaker for GSK. DFM has received funding to his institution from the NIHR, MRC, Wellcome Trust, Innovate UK, Northern Ireland Health and Social Care Research and Development Office, Novavax and Randox. In addition, DFM is a named inventor on a patent US8962032 covering the use of sialic acid-bearing nanoparticles as anti-inflammatory agents issued to his institution. DFM was a Director of Research for the Intensive Care Society and is the Director for the MRC\/NIHR EME Programme and is the Scientific Director for NIHR Programmes. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}